Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. The company also develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone800-556-0311
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$90.86 million
Profitability
Miscellaneous
Employees216
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Vericel (NASDAQ:VCEL) Frequently Asked Questions
What is Vericel's stock symbol?
Vericel trades on the NASDAQ under the ticker symbol "VCEL."
How were Vericel's earnings last quarter?
Vericel Corp (NASDAQ:VCEL) issued its earnings results on Tuesday, February, 26th. The biotechnology company reported $0.11 EPS for the quarter, topping the Zacks' consensus estimate of $0.04 by $0.07. The biotechnology company had revenue of $31.34 million for the quarter, compared to analyst estimates of $28.69 million. Vericel had a negative net margin of 8.96% and a negative return on equity of 7.58%. The company's quarterly revenue was up 34.2% compared to the same quarter last year. During the same period last year, the company posted $0.01 earnings per share. View Vericel's Earnings History.
When is Vericel's next earnings date?
What guidance has Vericel issued on next quarter's earnings?
Vericel updated its FY 2019 earnings guidance on Tuesday, February, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $108-112 million, compared to the consensus revenue estimate of $109.9 million.
What price target have analysts set for VCEL?
5 analysts have issued 12 month price targets for Vericel's shares. Their predictions range from $15.00 to $23.00. On average, they anticipate Vericel's stock price to reach $18.98 in the next year. This suggests that the stock has a possible downside of 2.0%. View Analyst Price Targets for Vericel.
What is the consensus analysts' recommendation for Vericel?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vericel.
What are Wall Street analysts saying about Vericel stock?
Here are some recent quotes from research analysts about Vericel stock:
- 1. According to Zacks Investment Research, "Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States. " (3/8/2019)
- 2. BTIG Research analysts commented, "$17 PT Heading into earnings, we viewed MACI’s ~23% Y/Y adjusted comp as achievable as the combo of increasing biopsy growth in YE17, rep additions, and low market penetration suggested another beatable Q. Viewed independent of the guidance raise, MACI’s 2Q18 result was in line with our Street-high expectations ($14.1M vs. BTIG’s $14.0M est.) but above Consensus ($13.7M) and while not bad, it may not excite investors looking for continued acceleration. That said, we do expect shares to be up tomorrow as guidance was raised ~9% (at the midpoint) to $80M – $83M (from $73M – $78M) as mgmt. sees strengthening momentum in 2H18 within MACI from biopsy strength, faster conversion times, new rep contributions, and continued marketing." (8/7/2018)
Has Vericel been receiving favorable news coverage?
News coverage about VCEL stock has trended somewhat positive on Thursday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vericel earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are some of Vericel's key competitors?
Some companies that are related to Vericel include Allogene Therapeutics (ALLO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Regenxbio (RGNX), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Alector (ALEC), Rubius Therapeutics (RUBY) and Iovance Biotherapeutics (IOVA).
What other stocks do shareholders of Vericel own?
Who are Vericel's key executives?
Vericel's management team includes the folowing people:
- Mr. Dominick C. Colangelo Esq., CEO, Pres & Director (Age 55)
- Mr. Gerard J. Michel, CFO & VP of Corp. Devel. (Age 56)
- Mr. Daniel R. Orlando, Chief Operating Officer (Age 54)
- Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel & Corp. Sec.
- Ms. Heidi Hassen, Sr. Director of HR
Who are Vericel's major shareholders?
Vericel's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.84%), RTW Investments LP (5.28%), Northern Trust Corp (1.27%), First Washington CORP (1.17%), Geode Capital Management LLC (1.15%) and Geode Capital Management LLC (1.15%). Company insiders that own Vericel stock include Alan L Rubino, Daniel Orlando, Dominick Colangelo, Gerard J Michel, Paul K Wotton and Steven C Gilman. View Institutional Ownership Trends for Vericel.
Which major investors are selling Vericel stock?
VCEL stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Two Sigma Investments LP, First Washington CORP, Millennium Management LLC, PNC Financial Services Group Inc., Timpani Capital Management LLC, Chartwell Investment Partners LLC and D. E. Shaw & Co. Inc.. Company insiders that have sold Vericel company stock in the last year include Daniel Orlando, Dominick Colangelo, Gerard J Michel, Paul K Wotton and Steven C Gilman. View Insider Buying and Selling for Vericel.
Which major investors are buying Vericel stock?
VCEL stock was bought by a variety of institutional investors in the last quarter, including Oberweis Asset Management Inc., Public Employees Retirement System of Ohio, American Century Companies Inc., Bank of New York Mellon Corp, BlackRock Inc., RTW Investments LP, Broadfin Capital LLC and GSA Capital Partners LLP. View Insider Buying and Selling for Vericel.
How do I buy shares of Vericel?
Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vericel's stock price today?
One share of VCEL stock can currently be purchased for approximately $19.37.
How big of a company is Vericel?
Vericel has a market capitalization of $847.44 million and generates $90.86 million in revenue each year. The biotechnology company earns $-8,140,000.00 in net income (profit) each year or ($0.14) on an earnings per share basis. Vericel employs 216 workers across the globe.
What is Vericel's official website?
How can I contact Vericel?
Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]
MarketBeat Community Rating for Vericel (NASDAQ VCEL)
MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote "Outperform" if you believe VCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
